Anti-CYP4F11 Polyclonal Antibody for IF/ICC, ELISA - Q9HBI6

Core Product Specifications and Parameters

Biological Background: CYP4F11 Function and Localization

• CYP4F11 is a cytochrome P450 monooxygenase that uses molecular oxygen and NADPH via cytochrome P450 reductase to insert one oxygen atom into substrates. It metabolizes various endogenous fatty acids and their oxygenated derivatives (oxylipins). Related references: PMID:15364545, PMID:18065749, PMID:24138531
• It catalyzes with high efficiency the omega-oxidation of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic acid, contributing to the biosynthesis of long-chain 3-hydroxydicarboxylic acids. Related references: PMID:18065749, PMID:19932081
• CYP4F11 inactivates vitamin K1 (phylloquinone) and vitamin K2 (menaquinone-4) through omega-hydroxylation, thereby modulating blood coagulation. Related references: PMID:24138531
• With low efficiency, it metabolizes arachidonic acid and its metabolite 8-HETE, suggesting a minor role in eicosanoid signaling. Related references: PMID:15364545, PMID:19932081
• The enzyme also catalyzes N- and O-demethylation of several drugs (e.g., erythromycin, benzphetamine, chlorpromazine), indicating involvement in xenobiotic metabolism. Related references: PMID:15364545
• Subcellularly, CYP4F11 resides in the endoplasmic reticulum and microsome membranes, a typical localization for cytochrome P450 enzymes.
• Tissue expression is predominantly hepatic, with detectable levels in kidney, heart, and skeletal muscle.
• As a heme-thiolate protein, CYP4F11 requires iron for its monooxygenase activity and uses NADPH as an electron donor.

Experimental Guidance and Technical Tips

• For immunofluorescence, optimize fixation and permeabilization conditions using a liver-derived cell line (e.g., HepG2) known to express CYP4F11.
• In ELISA applications, validate antibody binding using recombinant CYP4F11 protein or human liver microsome preparations as the coating antigen.
• Given its polyclonal nature, this antibody may recognize multiple epitopes; careful titration in your specific assay system is advised.
• The immunogen corresponds to a region within the N-terminal domain (aa 60–130); ensure this sequence is accessible in your target context (e.g., native vs. denatured protein).
• For detection, consider using a sensitive secondary antibody and appropriate controls to minimize background.
• Lot-to-lot consistency may vary; include internal reference standards when establishing new working dilutions.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers this anti-CYP4F11 polyclonal antibody alongside a comprehensive portfolio of IVD raw materials for metabolic and hepatic research. Our one-stop sourcing service covers validated antibody pairs, bulk ancillary reagents, and rare target procurement, supporting diagnostic developers from concept to clinic. Partner with CamelBio to streamline your raw material supply and accelerate assay development.